KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Free Cash Flow (2016 - 2025)

Amgen has reported Free Cash Flow over the past 17 years, most recently at $961.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $961.0 million for Q4 2025, down 78.16% from a year ago — trailing twelve months through Dec 2025 was $8.1 billion (down 22.07% YoY), and the annual figure for FY2025 was $8.1 billion, down 22.07%.
  • Free Cash Flow for Q4 2025 was $961.0 million at Amgen, down from $4.2 billion in the prior quarter.
  • Over the last five years, Free Cash Flow for AMGN hit a ceiling of $4.4 billion in Q4 2024 and a floor of $289.0 million in Q4 2023.
  • Median Free Cash Flow over the past 5 years was $2.1 billion (2021), compared with a mean of $2.2 billion.
  • Biggest five-year swings in Free Cash Flow: crashed 87.48% in 2023 and later soared 1422.49% in 2024.
  • Amgen's Free Cash Flow stood at $2.5 billion in 2021, then fell by 8.41% to $2.3 billion in 2022, then plummeted by 87.48% to $289.0 million in 2023, then soared by 1422.49% to $4.4 billion in 2024, then plummeted by 78.16% to $961.0 million in 2025.
  • The last three reported values for Free Cash Flow were $961.0 million (Q4 2025), $4.2 billion (Q3 2025), and $1.9 billion (Q2 2025) per Business Quant data.